Can a lower dose of this leukemia drug keep the disease at bay?

NCT ID NCT07383298

ENROLLING_BY_INVITATION Disease control Sponsor: Qian Jiang Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether reducing the dose of the drug olverembatinib can still control chronic myeloid leukemia in patients who have already responded well to treatment. About 100 adults with chronic or accelerated phase CML will switch to a lower dose (20 mg every other day) and be monitored for at least 12 months. The goal is to see if the leukemia stays under control with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olverembatinib
What this could lead to: If successful, this could show that a lower dose of olverembatinib is enough to keep chronic myeloid leukemia under control, potentially reducing side effects for patients.
What could go wrong: This is an early observational study with only 100 participants, so results may not apply to everyone. There is a risk that the lower dose might not keep the leukemia in remission for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA

Contacts and locations

Locations

Peking University People's Hospital

Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.